Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02079519 · OUTCOME

Progression-free Survival

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma · Source last updated 2014-07-08

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline to the end of the study (up to 1 year)

What was measured

Progression-free survival was defined as the time from the first dose of study drug to disease progression or death due to progression.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
description
Progression-free survival was defined as the time from the first dose of study drug to disease progression or death due to progression.
reporting Status
NOT_POSTED
time Frame
Baseline to the end of the study (up to 1 year)
title
Progression-free Survival
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice